DREAMM-10
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 520 patients (estimated)
- Sponsors
- GlaxoSmithKline
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2027
- NCT Identifier
- NCT06679101
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.